DOCSLIB.ORG

The Peres Center for Peace, Tel-Aviv April 12Th, 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Peres Center for Peace, Tel-Aviv April 12Th, 2019 April 12th, 2019 The Peres Center for Peace, Tel-Aviv BREAST CANCER INNOVATIONS The Israeli Society for Clinical Oncology and Radiation Therapy and Roche are Pleased to Invite You to an Enriching and Educating Meeting with our Distinguished Guest Speaker: Prof. Charles E. Geyer Please Send the Attached Registration Form to A.M Knasim No Later than April 1st 2019 E-mail: [email protected] Tel: 03-6081520 Fax: 03-6081522 Prof. Charles E. Geyer Friday, 12th April 2019 • Professor of Medicine 08:00-09:00 Welcome Reception • Harrigan, Haw, Luck Families Chair in Cancer Research 09:00-09:10 Opening Remarks • Virginia Commonwealth University, Massey Dr. Noa Efrat Ben-Baruch Cancer Center Head, Israeli Breast Cancer Group • Associate Director of Clinical Research Head, Department of Oncology Kaplan Medical Center Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Chairmen: Dr. Georgeta Fried Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director Head Breast Cancer Unit of Clinical Research for the Massey Cancer Center with oversight responsibility Rambam Medical Center for all cancer-related clinical research activities within the Center. Prof. Geyer Dr. Margarita Tokar has devoted most of his academic career on the design and conduct of multi- institutional, phase III clinical trials in breast cancer with a particular focus on Senior Oncologist the development of HER2 targeted therapies. He has served in several leadership Soroka University Medical Center positions for multi-institution research initiatives. These include vice-chair of the 09:10-09:30 Personalized Nanothechnologies in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee Management of Breast Cancer from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011. Currently he serves as Prof. Avi Schroeder Chair of the NSABP Foundation Breast Cancer Committee, and medical oncology The Wolfson Department of Chemical, vice-chair of the NRG Oncology Breast Cancer Committee. Engineering, Technion Chairmen: Dr. Larissa Ryvo In 2008, he was appointed as a founding Co-chair for the NCI Cancer Treatment Evaluation Program Breast Cancer Steering Committee and received a Director’s Head, Oncology Department Award at the completion of his tenure in 2011. Prof. Geyer has co-authored over Assuta Ashdod Academic Medical Center 80 peer-reviewed manuscripts including results of several landmark phase 3 Dr. Irina Lazarev trials conducted by the NSABP. He has also been active in leadership roles on Senior Oncologist collaborative global trials in breast cancer, having chaired or co-chaired Scientific The Legacy Heritage Oncology Center & Steering Committees on 5 phase III trials. He earned his bachelor’s and doctoral degrees from Texas Tech University in Lubbock, Texas and completed his internal Dr. Larry Norton Institute medicine residency and medical oncology fellowship at Baylor College of Medicine Soroka Medical Center & Ben-Gurion University Affiliated Hospitals in Houston, Texas. 4 5 Friday, 12th April 2019 (continued) 09:30-10:00 Modifying HER2 Positive Treatment in Early 10:40-11:00 Debate: Neo Adjuvant Therapy in HR Positive, Breast Cancer - Past, Present and Future HER2 Negative Breast Cancer Prof. Charles E. Geyer Moderator: Prof. Moshe Inbar Professor of Medicine Senior Oncology Consultant Harrigan, Haw, Luck Families Chair Assuta Medical Centers in Cancer Research Virginia Commonwealth University, Con: Dr. Karen Drumea Massey Cancer Center Director of the Oncology Associate Director of Clinical Research Outpatient Therapy Clinic Rambam Health Care Campus Chairmen: Dr. Noam Asna Head, Oncology Department Pro: Prof. Tamar Safra Barzilai Medical Center, Ashkelon Head, Onco-Gynecology Service Oncology Department Dr. Ora Rosengarten Tel Aviv Sourasky Medical Center Head of Medical Gyneco-Oncology Unit Shaare Zedek Medical Center 11:00-11:40 New Horizon in Early Breast Cancer 2019 - Dilemmas, Practical Considerations and Future 10:00-10:40 St. Gallen International Consensus: Prospects The Optimal Treatment of Woman with Breast Cancer – Oncological, Surgical and Moderator: Dr. Noa Efrat Ben-Baruch Radiotherapy Aspects Head, Israeli Breast Cancer Group Dr. Hadar Goldvaser Head, Department of Oncology Senior oncologist Kaplan Medical Center Davidoff Cancer Center, Breast Unit Panel: Prof. Charles E. Geyer Beilinson Hospital, Rabin Medical Center Professor of Medicine Prof. Dan Hershko Harrigan, Haw, Luck Families Chair Professor of Surgery, Head, Department of in Cancer Research Surgery A, Emek Medical Center, Afula Virginia Commonwealth University, Massey Cancer Center Dr. Raphael Pfeffer Associate Director of Clinical Research Head, Oncology Institute, Assuta Medical Center, Tel Aviv 6 7 Friday, 12th April 2019 (continued) Prof. Bella Kaufman 12:20-12:50 Optimizing Treatment of Triple Negative Head, Breast Oncology Institute Breast Cancer Sheba Medical Center, Tel Hashomer Prof. Charles E. Geyer Prof. Rinat Yerushalmi Professor of Medicine Director, Breast Cancer Unit Harrigan, Haw, Luck Families Chair Davidoff Center, Rabin Medical Center in Cancer Research Virginia Commonwealth University, Dr. Shani Paluch-Shimon Massey Cancer Center Director, Breast Oncology Unit Associate Director of Clinical Research Director, the Talya Center for Young Women with Breast Cancer, Shaare Zedek Medical Center 12:50-13:30 Case Studies Tumor Board Discussion - Illustrative Cases Incorporating Current and Prof. Beatrice Uziely New Data Head Oncology Ambulatory Services Unit Hadassah University Medical Center Case 1: The Role of Imunotherapy and PARP Inhibitors in Metastatic Triple Negative Breast Dr. Merav Ben-David Cancer Medical and Radiation Oncologist Dr. Rotem Merose Head, Breast Radiation Unit Senior Oncologist Chaim Sheba Medical Center Tel-Aviv Sourasky Medical Center Dr. Eran Sharon Case 2: The Challenge of Dealing with Rare TNBC Head, Breast Surgical Service Subtypes Rabin Medical Center Dr. Ofra Maimon Senior Oncologist 11:40-12:20 Brunch Break Sharett Institute of Oncology Chairman: Dr. Daniela Katz Hadassah University Medical Center Head of Breast and Sarcoma Services Moderator: Dr. Noa Efrat Ben-Baruch Assaf Harofeh Medical Center Head, Israeli Breast Cancer Group Head, Department of Oncology Kaplan Medical Center 8 9 Friday, 12th April 2019 (continued) Panel: Prof. Charles E. Geyer Professor of Medicine Harrigan, Haw, Luck Families Chair in Cancer Research Virginia Commonwealth University, Massey Cancer Center Associate Director of Clinical Research Prof. Tamar Peretz Head, Sharett Institute of Oncology Director, the Center for Malignant Breast Diseases Hadassah University Medical Center Dr. Einav Nili Gal-Yam Head, Ambulatory Care Unit Deputy Head, Breast Cancer Unit Institute of Oncology Sheba Medical Center, Tel Hashomer Dr. Ella Evron Senior Oncologist Kaplan Medical Center Dr. Judith Sandbank Head, Department of Pathology Maccabi Health Services Roche Pharmaceuticals (Israel) Ltd. 6 Hacharash Street P.O.B. 6391 Hod Hasharon 4524079 Israel www.roche.co.il MP-1903-V2-3106.
Load more

Recommended publications
  • Conference Time Table
    CONFERENCE TIME TABLE 6 April 7-8, 2019, Hilton Tel Aviv Hotel The 48th Annual Meeting of the Israel Endocrine Society PROGRAM AT A GLANCE Sunday, April 7, 2019 15:30-15:50 Coffee Break 07:30-08:30 Registration and Gathering 15:50-16:50 Meet the Expert Hall A Meet the Expert Hall B Novel Avenues in the Management of Endocrine Hypertension 08:30-10:00 Parallel Oral Presentations Congenital Adrenal Hyperplasia Felix Beuschlein Thyroid Reproduction Obesity, Metabolic Syndrome Nils P Krone University Hospital of Zurich Chairs: Dania Hirsch, Chairs: Talia Geva Eldar, Chairs: Yonit Marcus- Perlman, Sheffield, UK Carlos Benbassat Joseph Orly Rosane Abramof-Ness 16:50-17:30 IES Members General Assembly Hall A Hall A Hall B Hall C Executive Committee Report 10:00-10:20 Coffee Break Accountant Report 10:20-11:20 Poster Session Poster Hall Prize lectures Hall A 11:20-12:10 Chair: Avraham Karasik Lindner Prize, Eyal Robenshtok Chowers Prize, Yael Riahi Outstanding Community Physician Award, Elizabeta Baron Plenary lecture 1 Hall A Fat in the Blood, Fat in the Heart 12:10-13:00 Ira Goldberg, NYU School of Medicine, NYU Langone Health Chair: Hannah Kanety 13:00-14:00 Lunch 14:00-15:30 Parallel Symposia Symposium 1 Hall A Symposium 2 Hall B Congenital Adrenal Hyperplasia (CAH) Big Data – Digital Health in in 2019 Endocrinology Chairs: Naomi Weintrob, David Zangen Chairs: Moshe Phillip, Irit Hochberg 14:00-14:30 Nils P Krone Varda Shalev Molecular Pathogenesis of Rare Forms Big Data: From Research to Value of CAH Director of research and innovation institute Academic Unit of Child Health Maccabi and Morris Kahn.
    [Show full text]
  • The New Neonatal Care Center at Soroka Medical Center
    The New Neonatal Care Center at Soroka Medical Center 1 2 The New Neonatal Care Center at Soroka Medical Center The new Neonatal Care Center will serve all newborns in the Negev and provide full protection against missile attacks in accordance with the standards of the Home Front Command of the Israel Defense Forces. Soroka Medical Center: An Overview With 1,100 beds, Soroka Medical Center is among Israel’s largest and most advanced hospitals, and the country’s busiest. Soroka is the only major medical center in the entire Negev, serving a population of more than one million inhabitants, including 400,000 children, in a region that accounts for 60% of the country’s total land area. Soroka serves as the teaching hospital of both the Medical School of Ben-Gurion University, whose Faculty of Health Sciences is located on the hospital campus, and its Medical School for International Health. On par with leading international institutions, Soroka specializes in areas that include, for example, early detection and treatment of breast cancer using minimally invasive procedures; non-invasive removal of malignant tumors; trauma rehabilitation of children and adolescents; pediatric infectious diseases; and much more. Each year, excellent care is provided to more than 750,000 people at outpatient and clinic visits; 235,000 patients visit our Emergency Medicine Department (the busiest in the country); 80,000 inpatients fill our beds; over33 ,000 patients undergo surgery, and more than 17,000 babies are born. Soroka’s neonatal and pediatric departments provide family-centered intensive care with world-class survival rates. Soroka’s Trauma Unit is the largest and busiest in Israel, always on call, 24 hours a day, 365 days a year.
    [Show full text]
  • The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity
    S7 - Prognosis and Outcome in Heart Failure The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity Ayelet Itzhaki-Alfia 1, Jonathan Leor 1,Shiri Netser1, Leonid Sternik 2, Dan Spiegelstein 2, David Mishaly 2, Jacob Lavee 2, Ehud Raanani 2,Barbash Israel M3 1 Neufeld Cardiac Research Institute, Sackler Faculty of Medicine,Tel-Aviv University, 2 Department of Cardiothoracic Surgery, 3 Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 37 S7 - Prognosis and Outcome in Heart Failure The Impact of the NT-proBNP Assay in the Emergency Department on the Diagnosis of Heart Failure and on Outcomes in Patients Admitted for Dyspnea: A Prospective Randomized Placebo-controlled Double-center Trial (BNP4EVER) Simcha Meisel 1, Margarita Medvedovski 2, Moshe Sharist 3, Jalal Ashkar 2,Pavel Pschianski2, Michael Glikson 4, Shmuel Bar Haim 3, Michael Shochat 1, David Blondheim 1, Avraham Shotan 1 1 Heart Institute, Hillel Yaffe Medical Center, 2 Emergency Department, Hillel Yaffe Medical Center, Hadera, 3 Emergency Department, Assaf Harofeh Medical Center, Zerifin, 4 Heart Institute, Chaim Sheba Medical Center, Hadera, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 38 S7 - Prognosis and Outcome in Heart Failure Echocardiographic and Plasma N-Terminal Pro-B Type Natriuretic Peptide Evaluation During Pregnancy in Patients with Preexisting Dilated Cardiomyopathy Alex Blatt 1,Ilya Litovchik1, Ricardo
    [Show full text]
  • Curriculum Vitae Shay Schneider, M.D
    April, 2020 Curriculum Vitae Shay Schneider, M.D Name: Shay Schneider Date of birth: December 23, 1979 Place of birth: Tel Aviv, Israel Family status: Married +2 Telephone: +972-54-7685189 E mail: [email protected] CLINICAL EXPERIENCE Sep 2018-present: Senior staff member Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Sep 2018-Sep 2020: Clinical Fellow (Rhinology and skull base surgery), A.R.M, Center of Otolaryngology/ Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel. Sep 2012-Sep 2018: Resident: Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Jan 2011 - Jan 2012: Rotating internship year: Training physician in internal medicine, general surgery, anesthesia and pediatrics units, Barzilai Medical Center in Ashkelon, Israel. Jun 2009 - Aug 2009: Clinical rotation in Otolaryngology, Shaare Zedek Medical Center in Jerusalem, Israel. ACADEMIC DEGREES 2016- present: Instructor, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. 2004-2010: MD degree, Third Medical Faculty, Charles University in Prague (English program), Czech Republic. POST ACADEMIC COURSES Jan 2020: Baloon sinuplasty and Eustachian tuboplasty, Madeira, Portugal. Aug-Sep 2018: Observership, University of Texas MD Anderson Cancer Center, Houston, Texas. United States 2013-2018: School of Continuing Studies, Otolaryngology program, The Sackler Faculty of Medicine, Tel Aviv University, Israel. June 2017: Rhinoplasty course, Ziv Medical Center, Israel Feb 2017: 4th Annual OSAS International Surgery Course, Florida Hospital Nicholson Center & Florida Hospital Celebration Health, Celebration, United States. Feb 2017: Trans- oral laser surgery (TLS) course, Kaplan Medical Center. Sep 2016: Head and neck dissection course, Tel Aviv University. Oct 2014: Sedation course, Sheba Medical Center, Tel Aviv.
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy
    Obesity Surgery (2019) 29:3833–3841 https://doi.org/10.1007/s11695-019-04057-2 ORIGINAL CONTRIBUTIONS Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy Shiri Sherf-Dagan1,2,3 & Shira Zelber-Sagi1,4 & Assaf Buch5,6 & Nir Bar1,2 & Muriel Webb1 & Nasser Sakran7,8,9 & Asnat Raziel7 & David Goitein2,7,10 & Andrei Keidar11 & Oren Shibolet1,2 Published online: 11 July 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Background and Aims Longitudinal assessment of body composition following bariatric surgery allows monitoring of health status. Our aim was to elucidate trends of anthropometric and clinical outcomes 3 years following sleeve gastrectomy (SG). Methods A prospective cohort study of 60 patients who underwent SG. Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity were evaluated at baseline and at 6 (M6), 12 (M12), and 36 (M36) months post-surgery. Results Sixty patients (55% women, age 44.7 ± 8.7 years) who completed the entire follow-up were included. Fat mass (FM) was reducedsignificantly1yearpost-surgery(55.8±11.3to26.7±8.3kg;P < 0.001) and then increased between 1 and 3 years post- operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001). Fat free mass (FFM) decreased significantly during the first 6 months (64.7 ± 14.3 to 56.9 ± 11.8 kg; P < 0.001), slightly decreased between M6 and M12 and then reached a plateau through M36.
    [Show full text]
  • Governing Hospitals
    The Israel National Institute for Health Policy Research GOVERNINGGOVERNING HOSPITALSHOSPITALS INTERNATIONAL WORKSHOP REPORT Editor: Shlomo Mor-Yosef MARCH 2011, HAIFA, ISRAEL Graphic design: Nava Moscko Production: Zisman, Shiber GOVERNING HOSPITALS Dear Colleagues, Increasing market and regulatory pressures impose on hospitals all over the world important strategic challenges to the scope and quality of services rendered, cost control, equity and resource acquisition and allocation, financial stability, and many others. The following questions often rise: Are the current forms of hospital governance suitable to face these challenges? Should "philanthropic" hospitals, with a volunteer board, adopt a more active and critical form of governance typically found in the "corporate" model? Who should man the Board of Directors? Should legal and economic considerations prevail over professional and ethical ones? Should the hospital CEO be a doctor or a "professional" manager? The comprehensive study on “Governing Public Hospitals in Europe” conducted by Richard Saltman, Antonio Duran, David Chinitz and others in the European Observatory on Health Systems served as an initiator to this workshop. In Israel we have 4 different major forms of hospital governance facing the same doubts and soul searching. In this workshop, the heads of Israel’s health system, hospital directors and academicians deliberated these basic questions regarding hospital governance in great depth. This book comes to summarize the principle methods and various models for managing hospitals. Prof. Shlomo Mor-Yosef Chairman, Board of Directors The Israel National Institute for Health Policy Research 3 INTERNATIONAL WORKSHOP Table of Contents Page 1. Abstracts 7 2. Presentations 17 a. Governing Public Hospitals - An International Perspective Richard B.
    [Show full text]
  • Asuta Medical Release Form Request
    Asuta Medical Release Form Request Conjoint Christos engrosses that jubilee bull coyly and machicolated inurbanely. Gelatinous and overfar Marty travelling while unlovable hatfulWeidar stably. whiffle her Turkic whereunto and attitudinize substitutively. Indivertible Stephan never girdings so thermoscopically or falsifies any Log back shall your account. Additional meals and more open your privacy is not damage to cancel a specialization asuta medical release form request. Shaping agriculture around his world. Two patients who owns all authors asuta medical release form request. Our button with Assuta furthers our traction in the healthcare space, blank we do forward to helping more organizations like Assuta secure their critical systems and data. Furthermore LH release cab been demonstrated to swallow a beneficial effect on the. To sale more about this produce, you or the doctor may contact the county research staff using the contacts provided below. After our prepared remarks, we will open we call before your questions. They roll with patients from let over their world including Europe, the UK and the United States. Clalit tends to target a specialization in english asuta medical release form request timed out by using ultrasound to remove it? The sausage stage of treatment may own three options. Springer Nature remains neutral with hope to jurisdictional claims in published maps and institutional affiliations. This process of the israeli data, asuta medical release form request on the fax number associated with surgery? Tel Aviv never stops. All authors read and approved the final manuscript. But often suffer from israeli women asuta medical release form request new types of food places.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted
    [Show full text]
  • Antibiotic Treatment for Invasive Nonpregnancy-Associated Listeriosis and Mortality: a Retrospective Cohort Study
    European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:2243–2251 https://doi.org/10.1007/s10096-019-03666-0 ORIGINAL ARTICLE Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study Yaakov Dickstein1 & Yonatan Oster2 & Orit Shimon3 & Lior Nesher4 & Dafna Yahav3,5 & Yonit Wiener-Well6 & Regev Cohen7,8 & Ronen Ben-Ami3,9 & Miriam Weinberger3,10 & Galia Rahav3,11 & Yasmin Maor3,12 & Michal Chowers3,13 & Ran Nir-Paz2 & Mical Paul1,8 Received: 22 May 2019 /Accepted: 30 July 2019 /Published online: 10 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Little evidence exists addressing the clinical value of adding gentamicin to ampicillin for invasive listeriosis. A multicenter retrospective observational study of nonpregnant adult patients with invasive listeriosis (primary bacteremia, central nervous system (CNS) disease, and others) in 11 hospitals in Israel between the years 2008 and 2014 was conducted. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 h of culture results and continued for a minimum of 7 days. Patients who died within 48 h of the index culture were excluded. The primary outcome was 30-day all-cause mortality. A total of 190 patients with invasive listeriosis were included. Fifty-nine (30.6%) patients were treated with early combination therapy, 90 (46.6%) received monotherapy, and 44 (22.8%) received other treatments. Overall 30-day mortality was 20.5% (39/190). Factors associated with mortality included lower baseline functional status, congestive heart failure, and higher sequential organ failure assessment score.
    [Show full text]
  • Comprehensive Cancer Center This Is Untenable
    CompSorrehensokaive Cancer Center SOROKA MEDICAL CENTER Today’s Challenge Today’s FACTS Tel Aviv 60 Percent of Israel’s landmass 1,000,000 Total Population Jerusalem 300 Percent increase of cancer cases in the Negev over past 20 years due in large part to increase in population Last year at Soroka Medical Center: Gaza Soroka Hospitalizations in the Oncology and Medical 1,645 Hematology Wards Center Beer Patients cared for in the Ambulatory Sheva 15,923 Oncology and Hematology Units 24,451 Patients cared for in the Oncology and The Negev Hematology Clinics 17,987 Radiation therapy treatments 40,243 Chemotherapy treatments 100,249 Total number of cancer-related hospital visits miles a person in the southern tip of the Negev must 221 currently travel to reach a comprehensive cancer center This is untenable. 3 There is NO comprehensive cancer center in the Negev. Coping with cancer is difficult enough under the best of circumstances. There are the elements of fear and doubt, questions about how to handle it with the family and how to get the most effective treatment. The challenge is greatly compounded when the closest comprehensive cancer center is hours away and transportation is limited. Many residents in the Negev are impoverished and from traditional societies. If care is not easily accessible they simply will not get treatment. Chemotherapy treatment today 4 Growing Needs and Changing Winds Components for cancer treatment that do exist arose out of the Negev’s growing need for cancer care and they are scattered and overcrowded. Even more pressing is the fact that the Oncology Department is housed in Soroka Medical Center’s emergency underground hospital.
    [Show full text]